Aim: This study investigated coronary slow flow (CSF) prevalence in post-COVID-19 patients presenting with unstable angina (UA) and angiographically normal coronary arteries. Materials and methods: The study included 190 patients presenting with unstable angina (UA) and confirmed normal coronary arteries via invasive angiography. Participants were divided into two age- and sex-matched groups: 95 patients with a history of COVID-19 [COVID (+) UA-NCA] and 95 patients without a prior history of the infection [COVID (–) UA-NCA]. In the study group, COVID-19 was confirmed via RT-PCR and computed tomography. All participants underwent coronary angiography to perform Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) measurements. CSF was diagnosed in patients with a corrected TFC (CTFC) ≥ 27. Results: CSF prevalence was significantly higher in the COVID (+) UA-NCA group than in the COVID (–) UA-NCA group (18.9% vs. 5.3%, p = 0.003). Individual CTFC values for the LAD, LCX, and RCA were also significantly higher in the COVID (+) UA-NCA group compared to the COVID (–) UA-NCA group (26.1 ± 4.3 vs. 22.4 ± 2.6 [ p = 0.01], 24.3 ± 4.5 vs. 21.7 ± 2.4 [ p < 0.001], and 24.3 ± 4.5 vs. 21.4 ± 2.5 [ p < 0.001], respectively). Conclusions: CSF prevalence is significantly higher in patients with a history of COVID-19, suggesting persistent microvascular impairment.
Objectives: Coronary artery calcification (CAC) is associated with coronary atherosclerosis. There is a significant relation between coronary artery wall calcification and coronary artery disease (CAD). The measure of coronary artery calcification is an indicator of subclinical atherosclerosis. In some studies, it has been shown that coronary artery calcification is independent from conventional cardiovascular risks, which suggests data about prognosis. Matrix Gla protein (MGP) is an important protective modulator against calcification since it is an inhibitor of tissue calcification. In this respect, we aimed to establish the relationship between the distributions of nucleotide alterations found in promoter and coding regions of the MGP gene in patients with CAD and patients with normal coronary. Methods: DNA samples (n=115) were obtained from 58 patients with CAD and 57 healthy controls. The DNA samples obtained were analyzed by a Polymerase Chain Reaction (PCR) method using three sets of primer pairs, which cover the coding (Thr83Ala in exon 4) and promoter regions (T-138C and G-7A) of the MGP gene. Amplified regions were analyzed by a Restriction Fragment Length Polymorphism (RFLP) method for possible polymorphisms. Results: The chi-square analysis of the results revealed that there is no relationship between the observed polymorphisms and CAD. Conclusions: In this study, we investigated the relationship between MGP gene polymorphism and CAD. However, according to our findings, there was no statistically significant difference between the CAD and the control group.